What is the 13F Pro Quality Score for TNGX?

13F Pro ranks Tango Therapeutics, Inc. (TNGX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TNGX's current score at https://13fpro.ai/research/TNGX (free sign-up required for the full ranking).

Where does 13F Pro source TNGX data?

All Tango Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tango Therapeutics, Inc. files with the SEC under CIK 1819133. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TNGX in?

Tango Therapeutics, Inc. (TNGX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TNGX research updated on 13F Pro?

TNGX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tango Therapeutics, Inc.(TNGX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1819133 TNGX stock profile & AI dashboard →

13F Pro Quality Score

26.9/100

Rank #2,488 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

86.8/100

Profitability

5.8/100

Balance Sheet

8.4/100

Earnings Quality

30.0/100

Free Cash Flow

4.7/100

Institutional Flow

54.0/100

Revenue Scale

13.0/100

Dilution Risk

5.1/100

TNGX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tango Therapeutics, Inc. (TNGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNGX at 26.9/100 on a 32-signal composite quality model, placing it at rank #2,488 of 2,879 stocks — the bottom half of the AI-ranked universe. TNGX scores in the top quartile across revenue growth (86.8). Areas of concern include free cash flow (4.7) and profitability (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Tango Therapeutics, Inc. reports net income of $-45.5M, free cash flow of $-44.4M. Top institutional holders of TNGX by reported 13-F value include RTW INVESTMENTS,, ADAGE CAPITAL PARTNERS GP, L.L.C., Boxer Capital Management,, based on the most recent SEC filings. TNGX trades on the Nasdaq exchange and files with the SEC under CIK 1819133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tango Therapeutics, Inc. directly from SEC EDGAR. Tango Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 72 since 2022, currently 26.9 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Tango Therapeutics, Inc.

Quirks, history, and lore behind TNGX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on oncology.
2
The Numbers
A pre-revenue biotech with a relatively small market cap — the kind of company burning cash while its pipeline matures, with no approved products yet on the market.
3
The History
Founded around 2017, it was built on the premise that the next wave of cancer drugs would come from systematically identifying genetic vulnerabilities in tumors rather than chasing targets one by one.
4
The Secret
Its core platform leverages CRISPR-based functional genomics to find so-called synthetic lethal targets — genes that, when knocked out alongside a tumor mutation, cause cancer cells to self-destruct.
5
The Lore
The company was co-founded with deep ties to the Broad Institute and has partnered with Gilead Sciences, which made a significant equity investment to help advance its pipeline.
6
The Giveaway
Its name evokes a dance of precision, its ticker is a four-letter rhythm, and its lead program targets MTAP-deletion cancers — a genetic vulnerability found across multiple hard-to-treat tumor types.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-45.5M

Free Cash Flow

Q1 2026

$-44.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+70.8% YoY

$62.4MFY 2025

FY19 —FY21 $37.0MFY23 $36.5MFY25 $62.4M

Net Income

+0.1% YoY

$-101.6MFY 2025

FY19 —FY21 $-58.2MFY23 $-101.7MFY25 $-101.6M

Operating Income

+2.5% YoY

$-111.3MFY 2025

FY19 —FY21 $-58.2MFY23 $-114.2MFY25 $-111.3M

EPS (Diluted)

+19.4% YoY

$-0.87FY 2025

FY19 —FY21 $-0.94FY23 $-1.08FY25 $-0.87

Total Assets

-1.0% YoY

$398.7MFY 2025

FY19 —FY21 $500.2MFY23 $402.6MFY25 $398.7M

Op. Cash Flow

-17.7% YoY

$-138.9MFY 2025

FY19 —FY21 $-59.5MFY23 $-118.0MFY25 $-138.9M

Metric	FY 2025	FY 2023	FY 2021	FY 2019
Revenue	$62.4M +70.8%	$36.5M -1.4%	$37.0M	—
Net Income	$-101.6M +0.1%	$-101.7M -74.7%	$-58.2M	—
Operating Income	$-111.3M +2.5%	$-114.2M -96.2%	$-58.2M	—
EPS (Diluted)	$-0.87 +19.4%	$-1.08 -14.9%	$-0.94	—
Total Assets	$398.7M -1.0%	$402.6M -19.5%	$500.2M	—
Operating Cash Flow	$-138.9M -17.7%	$-118.0M -98.2%	$-59.5M	—

AI Insight: TNGX Ratio Trends

Tango showed profitability in Q3 2025 with 26.2% operating margin and 35.2% ROIC, but has since reverted to deep losses in Q4 2025 and Q1 2026.

• Q3 2025 marked dramatic turnaround: operating margin swung from -148.7% (Q2 2024) to +26.2%, NPM to +29.5%, ROIC to +35.2%.

• Profitability deteriorated sharply post-Q3 2025: ROE collapsed to -46.5% in Q1 2026 from +39.7% in Q3 2025; ROIC fell to -49.8%.

⚠ Q3 2025 profitability appears to be an isolated inflection, not sustained trend. Urgent need to understand Q4/Q1 2026 reversion drivers.

⚠ TTM profitability metrics remain deeply negative: -188.2% NPM, -30.0% ROIC, indicating Q3 2025 success did not anchor earnings.

Get alerted when TNGX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tango Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TNGX

RTW INVESTMENTS, LP
$278.2M13,300,620 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$268.0M12,809,485 sh
Boxer Capital Management, LLC
$227.5M10,876,219 sh
TCG Crossover Management, LLC
$220.3M10,531,071 sh
FMR LLC
$207.2M9,905,919 sh
FARALLON CAPITAL MANAGEMENT LLC
$190.3M9,097,411 sh
BlackRock, Inc.
$183.0M8,748,045 sh
Woodline Partners LP
$167.4M8,000,013 sh
Nextech Invest, Ltd.
$152.0M7,266,081 sh
TRV GP IV, LLC
$133.4M6,374,574 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$278.2M	13,300,620
ADAGE CAPITAL PARTNERS GP, L.L.C.	$268.0M	12,809,485
Boxer Capital Management, LLC	$227.5M	10,876,219
TCG Crossover Management, LLC	$220.3M	10,531,071
FMR LLC	$207.2M	9,905,919
FARALLON CAPITAL MANAGEMENT LLC	$190.3M	9,097,411
BlackRock, Inc.	$183.0M	8,748,045
Woodline Partners LP	$167.4M	8,000,013
Nextech Invest, Ltd.	$152.0M	7,266,081
TRV GP IV, LLC	$133.4M	6,374,574

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TNGX on your watchlist

Track score changes the day Tango Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TNGX a good stock to buy?

13F Pro's AI-powered analysis of Tango Therapeutics, Inc. (TNGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNGX are available on the TNGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TNGX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tango Therapeutics, Inc.'s investment landscape.